National Acalabrutinib Observational Study

Trial Identifier: D8220R00045
Sponsor: AstraZeneca
NCTID:: NCT05437250
Start Date: September 2022
Primary Completion Date: November 2026
Study Completion Date: November 2026
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France Aix-en-Provence, France
France Amiens, France
France Angers Cedex 9, France
France Ars-Laquenexy, France
France Avignon, France
France Beziers, France
France Bourg en Bresse, France
France Brest, France
France Caen, France
France Cahors, France
France Carcassonne, France
France Cesson Sevigne, France
France Chalon Sur Saone, France
France Chambery, France
France Clamart, France
France Clermont Ferrand, France
France Corbeil-Essonnes, France
France Dunkerque Cedex, France
France Essey-les-Nancy, France
France Grenoble, France
France La Chaussee-Saint-Victor, France
France La Tronche, France
France Le Chesnay-Rocquencourt, France
France Le Mans, France
France Le puy En Velay, France
France Lens, France
France Libourne, France
France Lille, France
France Limoges Cedex, France
France Lorient, France
France Marseille, France
France Meaux Cedex, France
France Mont-De-Marsan, France
France Nantes, France
France Nevers, France
France Nimes, France
France Orleans, France
France Perigueux, France
France Perpignan, France
France Pessac, France
France Pontoise, France
France Reims, France
France Rennes Cedex 9, France
France Roubaix, France
France Rouen, France
France Saumur, France
France Tarbes, France
France Toulouse, France
France Tours Cedex 9, France
France Troyes, France
France Valence, France
France Vandoeuvre Les Nancy, France
France Vantoux, France
France Vesoul, France
France Vichy, France